Atara Biotherapeutics, Inc.
ATRA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001604464
In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.
Superinvestors holding ATRA, Q2 2026
No superinvestor reported holding ATRA in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of ATRA each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q4 2023
0 superinvestors holding at quarter end
- Sold out
- Baupost Group, Maverick Capital
Q2 2023
2 superinvestors holding at quarter end
- Added
- Baupost Group (+7.1%)
Q1 2023
2 superinvestors holding at quarter end
- Added
- Baupost Group (+12.3%)
- Reduced
- Maverick Capital (0.0%)
Q4 2022
2 superinvestors holding at quarter end
- Reduced
- Maverick Capital (−19.9%)
Q1 2022
2 superinvestors holding at quarter end
- Reduced
- Baupost Group (−4.2%)
Q3 2021
2 superinvestors holding at quarter end
- Added
- Maverick Capital (+2.0%)
Q2 2021
2 superinvestors holding at quarter end
- Added
- Maverick Capital (+14.3%)